Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition

Executive Summary

Celgene is acquiring Abraxane developer Abraxis Biosciences and planning an aggressive development and marketing push for the novel nanoparticle formulation of paclitaxel, with the aim of driving the drug's sales to $1 billion by 2015
Advertisement

Related Content

Deal Watch: Amgen Takes Center Stage With Trio Of Transactions
Has Roche Set Up Celgene For Success In China?
Flush With Cash, Tesaro Advances Rolapitant Toward NDA
Celgene’s Abraxane Scores A Win Against Tough Pancreatic Cancer
Abraxane Lung Cancer Approval Comes With Questionable Commercial Value
In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas
Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas
AstraZeneca To Co-Promote Abraxis’ Paclitaxel

Topics

Advertisement
UsernamePublicRestriction

Register

PS052383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel